WE USE SEVERAL APPROACHES TO ATTACK THE DEADLIEST HUMAN CANCERS
Pancreatic cancer is the deadliest human cancer. Characterized by high mutation rate of the KRAS gene, there are currently no effective targeted therapies for pancreatic cancer.
We are investigating the interplay between common somatic mutations in pancreatic cancer, stroma and the microenvironment. Specific projects currently underway use a combination of unbiased screening with stromal and tissue biology in intact mouse models and xenografts.
We have had success growing primary patient cultures as well and are characterizing single cells; both benign and malignant, derived from patient biopsies.
The treatments available for patients with adenocarcinoma of the lung have improved dramatically over the last decade. Activating mutations in driver oncogenes are a cardinal characteristic of lung adenocarcinoma, and offer clear avenues towards personalized therapy for these patients.
The current work in the lab focuses on individualization of tumorigenesis and treatment. Using clinical sequencing coupled with rapid, recombinant cloning techniques, we are building models of individual patient tumors in the mouse genome. These systems will provide models for interrogating treatment response prior to, or concomitant with, novel therapies.